Drug Profile
Prostate cancer vaccine - Lumos Pharma
Alternative Names: HyperAcute ProstateLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator NewLink Genetics Corporation
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Prostate cancer
Most Recent Events
- 13 Dec 2012 Final efficacy, adverse events, pharmacodynamics and immunogenicity data from a phase I/II trial in Prostate cancer released by NewLink Genetics Corporation
- 22 May 2008 Immunogenicity data from a phase I/II trial in hormone-refractory Prostate cancer presented at the 103rd Annual Meeting of the American Urological Association (AUA-2008)
- 31 Mar 2005 Phase-I/II clinical trials in Prostate cancer in USA (SC)